Member Info for sajy

On the weekend, I will be releasing a video on a company that I invested into, a month ago, but not talked about yet.

The share price is up by over 100% since I invested but I believe there's still massive potential ahead (DYOR).

If you want to get notified when the video goes live please subscribe below:

https://youtube.com/@JustinSharePickers

I believe the company is Lunglife AI.

Laurence Hulse @laurence_hulse

Pleased to see @masterinvestor notice one of our latest core holdings @TransenseTech #TRT go into the Onward Opportunities portfolio - I look forward to sharing more details on our thesis in our half year results - took 3 months to build the position!!!

"Tackling antimicrobial resistance is a main priority of the five-year plan by the NHS in England.

In July 2023, the health service announced it was ramping up plans to start shifting to a subscription-based model for pharmaceutical company contracts in a bid to incentivise antibiotic development"

https://pharmaceutical-technology.com/news/uk-pledges-210m-global-antimicrobial-resistance-surveillance/ #DEST

@DestinyPharma

Holdings Rns - Dowgate above 3%.

Good find, thanks. I think we can expect an Rns on the day or just before. More than likely will discuss the data they have been talking about. Hopefully they are already in discussions with companies to sign deals.

It's been almost 12 months since we signed the MOU with Meggitt. I think it is reasonable to assume that if they were not interested in signing a deal they would have walked away by now. I am very confident that we will sign a mega deal for the SAW technology and expecting quite a spike on the day.

A decent write up on TRT, especially for newbies.

https://underfollowedstocks.substack.com/p/transense

Bagmann this is actually very good news for Destiny. Firstly as it has been pointed out this has been used in Canada for many years now and is not new news. Secondly I do not think this is as good as XF-73 in stopping post surgical infections, although it does help, XF-73 is over 99% effective. Thirdly a competitor is not bad news as their is always room for more than one drug in any indication, look at how many antibiotics are out there and they all make plenty of money.

The reason I like this news is that this trial shows how desperate the situation is regarding Antimicrobial Resistance (AMR)

that they are willing to try anything that will help. It shows they are crying out for drugs like XF-73. Also don't forget that XF-73 is likely to be used for 3 indications, post surgical infections, superficial skin infections and wounds. The total addressable market for all 3 is likely to be greater than $5Billion.

The more news about AMR the better and brings more attention to Destiny and XF-73. Finally this drug has been used for many years now in Canada and if it was that good it would have been bought out by the likes of GSK by now and they would not be interested in XF-73 as per the rumors.

I am convinced this drop is to fill an order. We shall see, I have added more today on that drop.

Good for you. I am waiting for the parabolic move that is coming. As you say news is needed and it is imminent on 2 fronts.

1. NIAID trial update any day now.

2. XF-73 partnering update with a Global pharma.

More than 40% of infection-related deaths in Americas associated with antimicrobial resistance"

XF‑73 from Destiny Pharma #DEST has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.

They have also clarified Phase 3 and US registration pathway for XF-73 nasal gel for the prevention of post-surgical staphylococcal infections.

EMA feedback on XF-73 nasal gel Phase 3 programme identifies a clear route through European approval as a novel hospital infection prevention product.

External European market research reports show that XF-73 nasal gel is seen as a very promising alternative to mupirocin, the current standard of treatment, by both clinicians and payers.

The study suggests XF-73 has the potential to replace the current standard of treatment as the preferred pre-surgical nasal decolonisation agent.

https://t.co/nfjzWsQGe7

Expected to start trading on Nasdaq on around the 8th September. Not long to go now.

100K buy just gone through. New Chairman opened his wallet?

See link below.

hTTps://masterinvestor.co.uk/equities/transense-technologies-sensing-the-time-is-right-to-buy/?mc_cid=c946f408b4&mc_eid=f446677a23

Agreed David Dest is very undervalued. It hit a high of £2.40 last time and the product pipeline is much more advanced now. This should be at least £3 on fair value. This valuation gap is going to close with all the news due, it's only a matter of time and patience. The long term holders should be rewarded handsomely.

I wonder if new Chairman and CEO have started buying?

What insiders? Do a bit of research and if you can't be bothered see my posts. I am expecting 3 bits of news that could come anytime.

1. NIAID update- imminent

2. XF-73 partnering update

3. Both new CEO and Chairman buys.

It is difficult for me to put in words the hugh potential XF-73 has.

We know that for post-surgical infections the market in US alone is $2B, as stated by Destiny.

The global acute bacterial skin and skin structure infections market is estimated to be valued at US$ 3,466 million in 2022

Prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs). this is the work being done by NIAID of USA - market size not sure.

In conclusion XF-73 could have a market of Greater than $5Billion. That is just for XF-73 and not including anything else Destiny have. Destiny valued at £42Million, go figure.

Antibiotic resistance is on the rise, doctor warns: ‘This is an enormous problem’

There are about 2.8 million antibiotic-resistant infections per year, according to the Centers for Disease Control and Prevention (CDC), which cause at least 35,000 annual deaths.

And those numbers are likely an understatement, according to Dr. Marc Siegel, a professor of medicine at NYU Langone Medical Center

The World Health Organization (WHO) describes antibiotic resistance as "one of the biggest threats to global health, food security and development today," according to its website.

https://t.co/Z0iLm1sapv

This is a rare beast on AIM and still well under the Radar.

It has a pathway to a 20 bagger, and the associated risks aren't huge, considering the potential reward.

They have 2 late stage assets, with excellent data, a big commercial market and now a top class board to execute the plan.